Mayo Clinic Laboratory and pathology research roundup: September 26

By Sarah Jarvis • September 26, 2023

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Semaglutide in HFpEF across obesity class and by body weight reduction: A prespecified analysis of the STEP-HFpEF trial.

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I-III (body mass index (BMI) 30.0-34.9 kg m^-2, 35.0-39.9 kg m^-2 and ≥40 kg m^-2) and according to body weight reduction with semaglutide after 52 weeks. 

Read more.

Published to PubMed This Week

• Open invitation to contribute ideas to a multifaceted approach to ethics in xenotransplantation.
  Xenotransplantation
• The effect of plasma exchange on serum levels of lacosamide: A case report.
  American Journal of Health System Pharmacy
• Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
  British Journal of Hematology
• Liver disease progression in patients with alpha-1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease.
  Alimentary Pharmacology & Therapeutics
• Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
  Oral Oncology
• Development of an LC-MS/MS assay with automated sample preparation for phosphatidylethanol (PEth)- Not your typical clinical marker.
  Journal of Chromatography
• Relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy.
  Prostate Cancer and Prostatic Diseases
• Baseline clinical factors are associated with risk of complications in Crohn's Disease: Appraisal of the AGA clinical care pathway.
  The American Journal of Gastroenterology
• Dataset for reporting of thymic epithelial tumours: Recommendations from the International Collaboration on Cancer Reporting (ICCR).
  Histopathology
• Seizure characteristics and outcomes in patients with neurological conditions related to high-risk paraneoplastic antibodies.
  Epilepsia
• TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
  Science Translational Medicine
• In vitro activity of hypochlorous acid generating electrochemical bandage against monospecies and dual-species bacterial biofilms.
  Journal of Applied Microbiology
• 'How to' guide for pharmacist-led Implementation of beta-lactam therapeutic drug monitoring in the critically ill.
  Journal of the American College of Clinical Pharmacy
• Subtype of SCLC is an intrinsic and persistent feature through systemic treatment.
  JTO Clinical and Research Reports
• Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis.
  Cardiooncology
• Imaging of alcohol-associated liver disease.
  American Journal of Roentgenology

Sarah Jarvis

Sarah Jarvis is a Senior Marketing Specialist at Mayo Clinic Laboratories. She supports marketing strategies for paid media.